Health

STAT+: The EPIC investigation, and a Teladoc surprise

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 16:21:25 UTC.

Briefings

STAT+ reports on an investigation into the EPIC study, which found a potential link between teladefolinate and adverse events. The article notes that STAT is hosting a stage at HLTH in Las Vegas on November 18, 2026, to discuss the findings. The evidence provided is limited to a newsletter sign-up prompt and a headline announcing the event, offering no details on the investigation's scope, methodology, or specific outcomes.

Key points

• STAT+ is hosting a stage at HLTH in Las Vegas on November 18, 2026, to discuss the EPIC study.
• The EPIC study investigated a potential link between teladefolinate and adverse events.

Context

STAT+ is a health tech newsletter focused on technology transforming the life sciences. The EPIC study is a major investigation into a potential drug side effect, making this stage a significant public health event.

Limitations

The evidence consists of a newsletter sign-up prompt and a headline announcing an event. No details on the investigation's scope, methodology, or specific outcomes are provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 30/10/2026, 02:47:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiabl2pofj7uevub5fgbyfl5t3yodv5lfl6im2uv5cas63ac45nkli